Listen to article
6:51Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
For most of my life, bacteria have been the villain of the story. We were taught to scrub them, bleach them, and, when they got inside us, obliterate them with antibiotics. Medicine’s approach was, to put it mildly, a bit of a sledgehammer. The strategy was simple, kill everything and hope for the best. It turns out, this carpet bombing of our internal ecosystems might have been a colossal, if well intentioned, mistake.
Science is now telling us what a few forward thinkers have suspected for a while. The trillions of microbes living in our gut are not just passive hitchhikers, they are a functioning, essential organ. This microscopic community, the microbiome, seems to influence everything from our digestion to our mood. And this realisation is kicking off what I think could be one of the most significant shifts in medicine. Instead of killing bacteria, pioneering companies are now engineering them as living, breathing therapeutics. It’s a fundamental change in perspective, moving from crude chemical warfare to sophisticated biological diplomacy.
So, what does this new world look like? Well, it’s far more precise. Consider the work being done with bacteriophages, which are viruses that hunt and destroy specific bacteria. Think of it as the difference between a B-52 bomber and a sniper. While antibiotics level the entire neighbourhood, good and bad microbes alike, phage therapy could take out a single troublesome strain without any collateral damage. To me, this represents a quantum leap.
The potential applications are staggering. Many chronic diseases, from inflammatory bowel conditions to stubborn skin complaints, are now being linked to imbalances in our microbial populations. If you can restore that delicate harmony, you might be able to address the root cause of an illness, not just paper over the symptoms with conventional drugs. It’s an approach that moves from managing sickness to actively restoring health, a subtle but profound difference.
Perhaps the most mind bending part of this whole revolution is the gut-brain axis. The idea that the bacteria in your intestines are producing chemicals that directly influence your brain sounds like something from a science fiction novel. Yet, the evidence is mounting. This connection helps explain why digestive problems and mood disorders so often go hand in hand.
This opens up an entirely new, and frankly fascinating, avenue for tackling mental health. Imagine a future where certain forms of depression or anxiety could be treated not by altering brain chemistry directly, but by modulating the patient’s gut flora. It’s a radical thought, challenging decades of psychiatric orthodoxy. Instead of looking at the brain in isolation, we might start treating it as part of a much larger, interconnected system.
Of course, with great potential comes great risk. Let’s be clear, investing in this space is not for the faint of heart. Most of these companies are in the clinical development stage, meaning they are burning through cash without a single product on the market. Their entire valuation hangs on the outcome of clinical trials, a process that is notoriously expensive and unpredictable. A single piece of bad news can send a stock plummeting.
However, the potential upside is what draws people in. The market for treatments addressing chronic disease is enormous. A company that gets a microbiome therapy through regulatory approval could see its valuation change dramatically. For investors looking to explore this high stakes field, a thematic approach can make sense. You can find a collection of companies in the Microbiome Modulators basket, which may offer a way to gain exposure to the sector's potential without betting the farm on a single clinical trial. But remember, success is far from guaranteed, and any investment carries the risk of loss.
View the full Basket:Microbiome Modulators
View the full Basket:Microbiome Modulators
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
